Metro (MRU) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
9 Jul, 2026Executive summary
Total sales reached CAD 6.65 billion, up 3.5% year-over-year, with food same-store sales up 2.4% and pharmacy up 5.2%.
Gross margin was stable at 19.6% of sales, and EBITDA rose 1.6% year-over-year (adjusted for asset sales).
Adjusted net earnings were CAD 305 million, down 3.1% from last year, with adjusted EPS flat at CAD 1.35.
Net earnings for the quarter were CAD 296.2 million, down 14.6% year-over-year, and fully diluted EPS was CAD 1.31, down 12.1%.
Online sales grew 35% year-over-year, supported by expanded click-and-collect and third-party delivery partnerships.
Financial highlights
Operating expenses rose 4.8% to CAD 681.7 million, mainly due to new automated distribution center startup costs and higher e-commerce fees.
Depreciation and amortization increased by CAD 14.5 million, reflecting investments in new DCs.
Net financial costs increased to CAD 46.6 million, up from CAD 37.1 million, due to higher debt and interest rates.
Operating income before depreciation, amortization, and impairments was CAD 620.2 million (9.3% of sales), up 1.3% year-over-year.
Share repurchases totaled 6.045 million shares for CAD 430 million under the current buyback program.
Outlook and guidance
Results are tracking well to fiscal 2024 guidance, with expectations to return to usual profit growth targets in fiscal 2025 as DC ramp-up costs subside.
Adjusted net earnings per share forecasted to be flat to down CAD 0.10 for Fiscal 2024 versus Fiscal 2023.
Medium- and long-term annual net earnings per share growth target maintained at 8% to 10%.
No significant lingering costs expected from DC automation projects into next year; focus will shift to efficiency gains.
CapEx for 2024 expected to be around CAD 650 million, with a normalized run rate of CAD 550–600 million in future years.
Latest events from Metro
- Q2 sales up 5.5%, adjusted EPS up 12.1%, and online sales grew 26.2% year-over-year.MRU
Q2 20259 Jul 2026 - Q4 saw strong sales and margin gains, supply chain completion, and profit growth expected in 2025.MRU
Q4 20248 Jul 2026 - Strong results, board re-elections, and strategic growth plans highlighted; auditor term limit proposal rejected.MRU
AGM 20258 Jul 2026 - Q2 sales rose 4.1% to CAD 5.1B, with strong pharmacy, discount, and online growth.MRU
Q2 202622 Apr 2026 - Sales up 2.9%, adjusted EPS up 7.8%, online sales up 18.6%, and dividend raised 10.4%.MRU
Q1 20254 Mar 2026 - Q3 sales rose 3.3%, adjusted EPS up 12.6%, with strong pharmacy and discount banner growth.MRU
Q3 20254 Mar 2026 - Q4 sales and earnings rose despite supply chain disruptions, with a strong FY 2026 outlook.MRU
Q4 20254 Mar 2026 - Sales up 3.3%, adjusted EPS up 5.5%, net earnings down 12.8% on one-time costs; dividend up 10.1%.MRU
Q1 20264 Mar 2026